Figures computed from official regulatory filings — .
Analysttarget 17.67 USD (+4%)
Ownershipinsiders 4.61% · institutions 94.71% · short 5.2% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Theravance Biopharma, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California. As of September 23, 2026, Theravance Biopharma, Inc. operates as a subsidiary of Zymeworks Inc.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
18 buys85 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| WEISS CAPITAL LLC | Other | $126.8M | SEC |
| O'Connor Donal | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| O'Connor Donal | Other | n/a (No price was disclosed in the filing) | SEC |
| O'Connor Donal | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| MITCHELL DEAN Jtrack record | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| O'Connor Donal | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Winningham Rick Etrack record | Other | n/a (No price was disclosed in the filing) | SEC |
| MITCHELL DEAN Jtrack record | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| O'Connor Donal | Other | n/a (No price was disclosed in the filing) | SEC |
| MITCHELL DEAN Jtrack record | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| O'Connor Donal | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Smaldone Alsup Laurie | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| GRAY SUSANNAH | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Sawaf Aziz | Other | n/a (No price was disclosed in the filing) | SEC |
| Grimaud Brett A. | Other | n/a (No price was disclosed in the filing) | SEC |
| Farnum Rhonda | Other | n/a (No price was disclosed in the filing) | SEC |
| Smaldone Alsup Laurie | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| O'Connor Donal | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Grimaud Brett A. | Other | n/a (No price was disclosed in the filing) | SEC |
| PAKIANATHAN DEEPIKAtrack record | Other | n/a (No price was disclosed in the filing) | SEC |
| Miller Aine | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Winningham Rick Etrack record | Other | n/a (No price was disclosed in the filing) | SEC |
| Smaldone Alsup Laurie | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Smaldone Alsup Laurie | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Smaldone Alsup Laurie | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |